Skip to content

Study on the role and mechanism of intestinal flora and its metabolites on the occurrence and development of senile sepsis

Study on the role and mechanism of intestinal flora and its metabolites on the occurrence and development of senile sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400084860
Enrollment
Unknown
Registered
2024-05-27
Start date
2024-05-30
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Sepsis group:None

Sponsors

Xijing Hospital of Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: sepsis group: (1) age =65 years; (2) Sepsis was diagnosed according to Sepsis3.0 criteria; (3) Agree to participate in this project and have signed the informed consent form. Non-sepsis group: (1) age =65 years; (2) Gender and comorbidities were matched with the patient group, and patients were in the stable stage of chronic diseases; (3) Agree to participate in this project and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: sepsis group: (1) recent (<1 month) history of immunosuppressive drugs and chemotherapy drugs; (2) combined with malignant tumors and immune system diseases; (3) those who are mentally ill or mentally retarded or otherwise unable to cooperate; (4) patients with acute or chronic intestinal diseases (Crohn's disease, ulcerative colitis, irritable bowel syndrome, etc.); (5) history of alcohol/drug abuse; (6) having received or being treated with fecal microbiota transplantation; (7) other conditions considered by the investigator to be unsuitable for enrollment. Non-sepsis group: (1) recent (<1 month) history of immunosuppressive drugs and chemotherapy drugs; (2) combined with malignant tumors and immune system diseases; (3) those who are mentally ill or mentally retarded or otherwise unable to cooperate; (4) patients with acute or chronic intestinal diseases (Crohn's disease, ulcerative colitis, irritable bowel syndrome, etc.); (5) history of alcohol/drug abuse; (6) having received or being treated with fecal microbiota transplantation; (7) other conditions considered by the investigator to be unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Endotoxin(LPS);Intestinal fatty acid-binding protein(I-FABP);Diamine oxidase(DAO);D-lactic acid;

Secondary

MeasureTime frame
Adverse events;

Countries

China

Contacts

Public ContactXiaoxuan Ning

The First Affiliated Hospital of Air Force Medical University

ningxx01@fmmu.edu.cn+86 136 7922 0705

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026